CompletedNot Applicable

A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

China113 participantsStarted 2024-07-19

Plain-language summary

This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Initiating both Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 regardless of sequencing, number of doses/cycles, and type of TACE
✓. At least one dose of Atezo+Bev and one cycle of TACE spaced no longer than 4 weeks
✓. Diagnosed with HCC and considered as unresectable by any of the below criteria:

Exclusion criteria

✕. No visit record after initiating both Atezo+Bev and TACE
✕. Treated with other systemic therapy or resection against HCC
✕. Diagnosed with concomitant cancer except for basal cell carcinoma
✕. Advanced portal vein tumor thrombosis (PVTT) as defined by: Grade Vp 4, Cheng's Classification Type III or IV, or presence of a tumor thrombus in the main trunk of the portal vein, a portal vein branch contralateral to the primarily involved lobe, or superior mesenteric vein
✕. China Liver Cancer (CNLC) Stage IIIb, or history of extrahepatic metastasis
✕. Terminal-stage HCC

What they're measuring

Median Time to Real-World Progression-Free Survival (rwPFS)

Timeframe: up to approximately 12 months

Trial details

NCT IDNCT06503250

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-11-27

View on ClinicalTrials.gov More Unresectable Hepatocellular Carcinoma trials